Publication | Closed Access

RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients with Chronic HBV Infection

Viral PersistenceChronic Hbv InfectionAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirologyBone SafetyTenofovir Alafenamide ComparedChronic Viral InfectionInfection ControlAntiviral DrugMedicine